Skip to main content
Tech.euFundingExplorerBeta

Healthtech funding in Q2 2026

European Healthtech startup funding raised during Q2 2026.

In Q2 2026, 102 European Healthtech companies closed 104 funding rounds and raised €2.7B in equity funding (excluding debt and grants), up 86.0% versus Q2 2025. Debt rounds added €32M. UK led by capital raised, and High-Tech Gründerfonds (HTGF) was the most active investor. Data as of 20 Nov 2026.

Equity funding
€2.7B
+86.0% vs Q2 2025 · excl. debt & grants · +€32M debt
Funding rounds
104
-18.1% vs Q2 2025
Companies
102
Top country
UK
Rank among sectors
#3
11.0% of sector funding
Debt financing
€32M
1.2% of total
Top-10 round share
81.3%
of disclosed capital
Rounds ≥ €100M
1

Funding by month

€ raised vs rounds, by month
Healthtech — funding by month, Q2 2026 — interactive chart.
Data table
FundingRounds
Apr€253M35
May€2.0B33
Jun€486M36

Top countries

by € raised
Healthtech — top countries by capital, Q2 2026 — interactive chart.
Data table
Healthtech — top countries by capital, Q2 2026
UK€2.1B
France€161M
Switzerland€137M
Spain€124M
Germany€118M
Netherlands€50M
Sweden€31M
Italy€17M

Stage mix

by € raised
Healthtech — stage mix, Q2 2026 — interactive chart.
Data table
Healthtech — stage mix, Q2 2026
Series B€1.9B
Other€301M
Series A€155M
Seed€95M
Series D+€86M
Series C€82M
Growth/Late€52M
Debt€32M
Pre-Seed€15M
Grant€5.0M
Crowdfunding€233k

Exits & M&A

9 Acquisition

9 exits · €504M disclosed.

Saga DiagnosticsAcquisitionApr 2026€504M

Top deals

largest disclosed rounds in Q2 2026
CompanyStageDateAmount
Isomorphic LabsSeries BMay 2026€1.8B
CeQurSeries D+Jun 2026€86M
Ona TherapeuticsSeries BJun 2026€74M
UromemsGrowth/LateMay 2026€52M
Storm TherapeuticsSeries CApr 2026€48M
NVision ImagingSeries BMay 2026€47M
IMU BiosciencesOtherJun 2026€45M
Leyden LabsOtherJun 2026€40M
SembleSeries CJun 2026€35M
TissiumOtherJun 2026€30M
TissiumDebtJun 2026€30M
NUCLIDIUMSeries BMay 2026€29M
Prosper AISeries AJun 2026€26M
Lightcast DiscoveryOtherApr 2026€23M
EnteroBiotixOtherMay 2026€22M

Top investors

most active in Q2 2026, by deal count